Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles

21Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Currently, therapy for thyroid cancer mainly involves surgery and radioiodine therapy. However, chemotherapy can be used in advanced and aggressive thyroid cancer that cannot be treated by other options. Nevertheless, a major obstacle to the successful treatment of thyroid cancer is the delivery of drugs to the thyroid gland. Here, we present an example of the construction of silicon dioxide nanoparticles with thyroid–stimulating-hormone receptor-targeting ligand that can specifically target the thyroid cancer. Doxorubicin nanoparticles can be triggered by acid to release the drug payload for cancer therapy. These nanoparticles shrink the tumor size in vivo with less toxic side effects. This research paves the way toward effective chemotherapy for thyroid cancer.

Cite

CITATION STYLE

APA

Li, S., Zhang, D., Sheng, S., & Sun, H. (2017). Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles. International Journal of Nanomedicine, 12, 5993–6003. https://doi.org/10.2147/IJN.S137335

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free